

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the administration or supply of

Ketamine 10mg/1ml IV / IO

By registered health care professionals for

Analgesia for severe pain

For Paramedic Services use only

PGD NUMBER 143

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

Reference number: 143 Valid from: 06/2021 Review date: 06/2023

2. Medicines practice guideline 2: Patient group directions

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care <u>PGD</u> website FAQs

3. PGD development

Refer to the <u>NICE PGD competency framework for people developing PGDs</u>

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the NICE PGD competency framework for people authorising PGDs

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

Reference number: 143 Valid from: 06/2021 Review date: 06/2023

5. PGD adoption by the provider

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job title and organisation	Signature	Date	Applicable or not applicable to area

6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the <u>NICE PGD competency framework for health professionals using PGDs</u>

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are
professional registration	permitted staff groups outlined within the current PGD policy
	Procedural sedation training
	Advanced life support training
	For Paramedic Services use only
Initial training	 Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria
	 Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD
	Local training in the use of PGDs
	 Successful completion of the Isle of Man Ambulance Service Sudation Training and competency assessment
Competency	Staff will be assessed on their knowledge of drugs and clinical
assessment	assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and	The registered health care professionals should make sure they are
competency	aware of any changes to the recommendations for this medication;
, ,	it is the responsibility of the registered health care professionals to
	keep up to date with continuing professional development. PGD updates will be held every two years

Reference number: 143 Valid from: 06/2021 Review date: 06/2023

7. Clinical Conditions

Clinical condition or situation to which this PGD applies	Analgesia for severe pain
Inclusion criteria	Analgesia for severe pain, particularly in relation to trauma
	and/or burns
Exclusion criteria	12 years and older Children and on trucks (42) years.
Exclusion criteria	Children under twelve (12) years Where other analysis may be suitable.
	Where other analgesia may be suitable Known sovers allergis reaction to ketamine
	Known severe allergic reaction to ketamine Known glausema or isolated eve injury
	Known glaucoma or isolated eye injury
	PregnancyBreast feeding
Cautions (including any	_
relevant action to be	 Adults and children aged twelve (12) years or over who are trapped and/or not about to be/able to be laid flat
taken)	 Hypertension
, cancer,	Heart Disease
	Porphyria
	Psychotic disorders
	Risk of laryngospasm
	Thyroid disorders
	Alcohol consumption and chronic alcohol dependency
Arrangements for referral	Patient should be referred to a more experienced clinical
for medical advice	practitioner for further assessment
Action to be taken if	Patient should be referred to a more experienced clinical
patient excluded	practitioner for further assessment
Action to be taken if	A verbal explanation should be given to the patient on: the need
patient declines	for the medication and any possible effects or potential risks
treatment	which may occur as a result of refusing treatment
	 This information must be documented in the patients' health records
	Any patient who declines care must have demonstrated capacity to do so
	Where appropriate care should be escalated

8. Details of the medicine

Name, form and strength	Ketamine 10mg/ml
of medicine	
Legal category	Controlled drug (CD) (Schedule 2)
Indicate any off-label use	Severe pain
(if relevant)	
Route/method of	Intravenous (IV) or intraosseous (IO)
administration	

Reference number: 143 Valid from: 06/2021 Review date: 06/2023

_ 16 1			
Dose and frequency ¹	Dosage:		
	0.1mg/kg up to a maximum of 10mg (1ml) per dose		
	Wait at least one minute between doses		
	Subsequent doses:		
	0.1mg/kg up to a maximum dose of 10mg (1ml) given slowly		
	Wait at least one minute between doses		
	A maximum of 6 doses (total 60mg) without seeking clinical advice		
Quantity to be	As per dose		
administered and/or			
supplied			
Maximum or minimum	A maximum of 6 doses (total 60mg) without seeking clinical		
treatment period	advice		
	If patient condition indicates, and following discussion with		
	senior clinician, maximum of 10 doses (total 100mg) can be		
	given		
Storage	Room temperature		
Adverse effects	 Arrhythmias Predisposition to seizures, 		
	Bradycardia – less common hallucinations and psychotic		
	Diplopia disorders		
	Emergence phenomenon Rash		
	Hypertension Respiratory depression		
	Hyper salivation (usually from rapid)		
	Hypotension – less common administration)		
	Laryngospasm Tachycardia		
	Nausea Vomiting		
	Nystagmus		
Records to be kept	The administration of any medication given under a PGD must be		
	recorded within the patient's medical records		

9. Patient information

Verbal/Written information to be given to patient or carer	 Verbal information must be given to patients and or carers for all medication being administered under a PGD Where medication is being supplied under a PGD, written patient information leaflet must also be supplied A patient information leaflet is available on request
Follow-up advice to be	If symptoms do not improve or worsen or you become unwell, seek
given to patient or carer	medical advice immediately

Reference number: 143 Valid from: 06/2021 Review date: 06/2023

 $^{^{\}rm 1}\,{\rm Agreed}$ by the Isle of Man Ambulance Clinical Effectiveness Group

10. Appendix A

References

- 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk
- 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
- 3. Current Health Care Professions Council standards of practice
- 4. General Pharmaceutical Council standards
- 5. The General Optical Council
- 6. Electronic medicines compendium available online: https://www.medicines.org.uk

11. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves

Reference number: 143 Valid from: 06/2021 Review date: 06/2023